ライフサイエンスコーパス: tramadol

1 2010 usually for hydrocodone, oxycodone, or tramadol.

2 was lower for tricyclic antidepressants and tramadol.

3 done, hydromorphone, fentanyl, morphine, and tramadol.

4 metabolites, such as the ones of cocaine and tramadol.

5 ase in naproxen dosage after the addition of tramadol.

6 ng to naproxen 1,000 mg/day, the addition of tramadol 200 mg/day allows a significant reduction in th

7 domized in a double-blind manner to continue tramadol 200 mg/day or to begin placebo in addition to n

8 Tramadol 200 mg/day was added during the third week.

9 (237 +/- 20 min), APAP/C (311 +/- 26 min) or tramadol (311 +/- 10 min) (p = 0.12).

10 bo (69 +/- 7 min), APAP/C (74 +/- 15 min) or tramadol (686 +/- 8 min) (p = 0.86) were seen.

11 eeded to treat: 4), meperidine (16; 2.2, 2), tramadol (8; 2.2, 2), nefopam (7; 2.1, 2), and ketamine

12 ved placebo (n = 157), patients treated with tramadol/acetaminophen (n = 156) showed greater improvem

13 Patients received either tramadol/acetaminophen or placebo 4 times/day as needed

14 The obtained degradation pathway of tramadol allowed the correlation of changes in NDMA FP d

15 Tramadol and APAP/C had no effect on gastric emptying or

16 The GC for tramadol and APAP/C were all significantly lower at 72 h

17 When treated with the FDA-approved drugs tramadol and escitalopram oxalate, they release or uptak

18 hloramine decreased the degradation rates of tramadol and its byproducts and yielded several monochlo

19 r tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for li

20 tly studied include remifentanil, methadone, tramadol, and codeine.

21 Systemic baclofen, gabapentin, tramadol, and morphine dose-dependently attenuated tacti

22 s, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal

23 Although codeine and tramadol are frequently used in the postoperative period

24 methylamine formation potential (NDMA FP) of tramadol as a model precursor.

25 The GC of tramadol at 24 and 48 hr (3.8 +/- 0.4, 5.4 +/- 0.26) wer

26 We also found fair evidence that opioids, tramadol, benzodiazepines, and gabapentin (for radiculop

27 At equianalgesic doses, tramadol caused less delay in colonic transit than APAP/

28 ne therapy within the clonidine (8 [22.2%]), tramadol ER (7 [19.4%]), or buprenorphine (3 [9.7%]) gro

29 A 7-day taper using clonidine (n = 36), tramadol ER (n = 36), or buprenorphine (n = 31) was then

30 ]; taper mean, 1.54 [SE, .10]; P < .001) and tramadol ER (stabilization mean, 0.53 [SE, .05]; taper m

31 n, 13.1; post-taper mean, 3.2; P < .001) and tramadol ER (taper mean, 7.4; post-taper mean, 2.8; P =

32 Data support further examination of tramadol ER as a method to manage opioid withdrawal symp

33 The results of this trial suggest that tramadol ER is more effective than clonidine and compara

34 ed with clonidine participants (22 [61.1%]); tramadol ER retention was intermediate and did not diffe

35 hmics class III [amiodarone], other opioids [tramadol], glucocorticoids, triazole derivatives, and co

36 nresponders, the mean MEND was 419 mg in the tramadol group and 396 mg in the placebo group (P = 0.70

37 f several drugs on gastrointestinal transit (tramadol HCl, acetaminophen with codeine and placebo) in

38 To evaluate whether tramadol hydrochloride extended-release (ER), an approve

39 electrode was used for the determination of tramadol in infected and healthy human urine and pharmac

40 e identified as major reaction mechanisms of tramadol in UV oxidation.

41 products (BTPs) of organic micropollutants (tramadol, irgarol, and terbutryn).

42 Tramadol is an alternative to musculoskeletal pain manag

43 al anti-inflammatory agents, gabapentinoids, tramadol, lidocaine, and/or the N-methyl-d-aspartate cla

44 ds (such as codeine, dextropropoxyphene, and tramadol) may be effective in the short-term management

45 ribed were codeine, oxycodone, propoxyphene, tramadol, morphine, meperidine, fentanyl, or hydroxycodo

46 as significantly lower in patients receiving tramadol (n = 36) than in patients receiving placebo (n

47 Clonidine, meperidine, tramadol, nefopam, and ketamine were the most frequently

48 inflammatory drugs as first-line therapy, or tramadol or duloxetine as second-line therapy.

49 topical nonsteroidal anti-inflammatory drug, tramadol, or both is recommended.

50 -codamol, paracetamol, codeine, co-dydramol, tramadol, oxycodone, and morphine) during 2005-2010 comp

51 Tramadol, previously only known as a synthetic analgesic

52 nd to be 0.004 and 0.01 to 20 mumol L(-1) of tramadol, respectively.

53 The kinetics and oxidation products (OPs) of tramadol (TRA), an opioid, were investigated for its oxi

54 nsteroidal anti-inflammatory drugs (NSAIDs), tramadol, traditional opioids, or adjunctive analgesics.

55 and UV/H(2)O(2)/monochloramine oxidation of tramadol using MS(3) capabilities of a hybrid quadrupole

56 hly selective and sensitive determination of tramadol using square wave voltammetry.

57 Tramadol was transformed more and faster than irgarol an